Quantum Biopharma (QNTM) Cash & Current Investments (2018 - 2026)

Quantum Biopharma has reported Cash & Current Investments for 9 years, with the latest figure at $4.6 million in Q1 2026.

• Quarterly Cash & Current Investments rose 28.98% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (up 28.98% YoY) and the FY2025 annual result came in at $2.4 million, down 67.15% from the prior year.
• Cash & Current Investments improved to $4.6 million in Q1 2026 per QNTM's latest filing, from $2.4 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $32.0 million in Q2 2022 and troughed at $1.1 million in Q3 2025.
• A 5-year average of $10.2 million and a median of $6.2 million in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments soared 51.04% in 2024, then plunged 83.61% in 2025.
• Over 5 years, Cash & Current Investments stood at $17.0 million in 2022, then tumbled by 74.24% to $4.4 million in 2023, then jumped by 64.59% to $7.2 million in 2024, then slumped by 67.15% to $2.4 million in 2025, then surged by 93.06% to $4.6 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $4.6 million, $2.4 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.